Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network. The agreement does not include cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators and is unrelated to the company’s investigational products or other ongoing research programs in cystic fibrosis.

The Proteostasis Network (PN) consists of more than 1,000 proteins organized into pathways that can be regulated or targeted by drugs.  The network is to ensure that every . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.